TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6520821
Drug: Short course
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short course of intravenous cefoxitin prophylaxis and intraoperative saline irrigation
Study: 25253199
Drug: Initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial combination therapy (iCombo)
Study: 25253199
Drug: Initial monotherapy
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial monotherapy (iMono)
Study: 23173697
Drug: Tradamixina (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tradamixina (150 mg of Alga Ecklonia Bicyclis, 396 mg of Tribulus Terrestris and 144 mg of D‐Glucosamine and N‐Acetyl‐D‐Glucosamine) twice a day for 2 months
Study: 23173697
Drug: Tadalafil 5
Normalized name: tadalafil 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 5 mg daily for 2 months
Study: 20438867
Drug: OAM (Omeprazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAM (Omeprazole, Amoxicillin and Metronidazole)
Study: 17353942
Drug: d-amphetamine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (0.3 mg/kg, given orally) plus a nutritionally balanced amino acid mixture
Study: 17353942
Drug: L-DOPA (Sinemet,
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-DOPA (Sinemet, 2 x 100 mg/25 mg)
Study: 16223394
Drug: Inferior-medial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inferior-medial injection technique
Study: 16223394
Drug: Inferior-superior injection
Normalized name: Sus scrofa superior gastric plexus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inferior-superior injection technique
Study: 1922801
Drug: Slow-release bromocriptine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release bromocriptine (14.2 +/- 0.7 mg/d, taken twice a day)
Study: 1922801
Drug: Standard bromocriptine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard bromocriptine (13.5 +/- 0.7 mg/d, taken three times a day)
Study: 6297068
Drug: Dacarbazine (DTIC)
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dacarbazine (DTIC) + Detorubicin (120 mg/m2, IV every three weeks)
Study: 6297068
Drug: Dacarbazine (DTIC)
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dacarbazine (DTIC) alone (250 mg/m2, IV, over 4 days every three weeks)
Study: 31964380
Drug: AL +
Normalized name: Citracal + D
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL + day 1 primaquine (0.75 mg/kg)
Study: 31964380
Drug: AL +
Normalized name: Citracal + D
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL + day 3 primaquine (0.75 mg/kg)
Study: 11442551
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of aspirin every other day (n = 525)
Study: 11442551
Drug: Aspirin placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin placebo (n = 476)
Study: 10357955
Drug: Prednisolone 10
Normalized name: prednisolone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 10 mg at night
Study: 7498099
Drug: Olestra (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olestra (24 g) with moderate fibre (7 g/meal)
Study: 7498099
Drug: Olestra (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olestra (24 g) with high fibre (24 g/meal)
Study: 7498099
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with moderate fibre (7 g/meal)
Study: 7498099
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with high fibre (24 g/meal)
Study: 7498099
Drug: Olestra (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olestra (24 g)
Study: 30951167
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg per-oral morphine
Study: 30951167
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg per-oral naltrexone
Study: 20696421
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment program (after waitlist)
Study: 18281409
Drug: Atomoxetine (0.8-1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (0.8-1.8 mg/kg per day)
Study: 18281409
Drug: Osmotically released
Normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Osmotically released methylphenidate (18-54 mg/day)
Study: 1473428
Drug: Low-dose Al
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Al antacid (1 tablet four times a day)
Study: 76166
Drug: Cimetidine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (800 mg at bedtime)
Study: 6426646
Drug: 14 valent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 valent pneumococcal vaccine
Study: 16521845
Drug: CHO (9.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO (9.3% carbohydrate solution)
Study: 16521845
Drug: CHO-PRO (9.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO-PRO (9.3% carbohydrate solution plus 1.5% protein)
Study: 10494641
Drug: Supplementary oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementary oxygen (2 L/min)
Study: 8740798
Drug: Paclitaxel at
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel at dose levels of 135, 170, 200, 250, and 300 mg/m2 (24-hour infusion); 250 mg/m2 (one-hour infusion)
Study: 8740798
Drug: Ifosfamide at
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ifosfamide at a dose of 1.6 g/m2 i.v. bolus daily for 3 days with mesna uroprotection
Study: 8391065
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy (seven further cycles of CDE: cyclophosphamide 1 g/m2, doxorubicin 45 mg/m2, etoposide 100 mg/m2)
Study: 8391065
Drug: Follow-up (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up (no further chemotherapy)
Study: 8391065
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy (seven further cycles of CDE)
Study: 21795458
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of the 2009 monovalent pandemic influenza A/H1N1 MF59-adjuvanted vaccine (PV) coadministered with 1 dose of the seasonal 2009-2010 trivalent nonadjuvanted influenza vaccine (SV)
Study: 21795458
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of the 2009 monovalent pandemic influenza A/H1N1 MF59-adjuvanted vaccine (PV) coadministered with 1 dose of the seasonal 2009-2010 trivalent nonadjuvanted influenza vaccine (SV)
Study: 21795458
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of the seasonal 2009-2010 trivalent nonadjuvanted influenza vaccine (SV)
Study: 21795458
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of the 2009 monovalent pandemic influenza A/H1N1 MF59-adjuvanted vaccine (PV) and 2 doses of PV
Study: 15265241
Drug: telithromycin 800
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: telithromycin 800 mg once daily for 5, 7, or 10 days
Study: 15265241
Drug: telithromycin 800
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: telithromycin 800 mg once daily for 7-10 days
Study: 15265241
Drug: clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: clarithromycin 500 mg twice daily for 10 days
Study: 8033435
Drug: Control treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatments (anti-cholinesterase drugs, thymectomy, corticosteroids, immunosuppressants, plasma exchange)
Study: 2645845
Drug: Nutritional intervention
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional intervention in place of antihypertensive drugs
Study: 24640268
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml dexamethasone/bupivacaine/gentamicin (DMG) solution
Study: 24640268
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml saline solution
Study: 16167963
Drug: Placebo (sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sterile water in 25 mL saline)
Study: 2091361
Drug: Citrate-containing glucose
Normalized name: fructose / glucose / sodium citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrate-containing glucose electrolyte solution (GES)
Study: 2091361
Drug: Maize-salt solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maize-salt solution (MSS)
Study: 381074
Drug: Commercialized anatoxin
Normalized name: aflatoxin B1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercialized anatoxin (30 Lf per dose, adsorbed on Ca phosphate)
Study: 381074
Drug: Commercialized anatoxin
Normalized name: aflatoxin B1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercialized anatoxin (30 Lf per dose, adsorbed on Al hydroxide)
Study: 381074
Drug: Experimental anatoxin
Normalized name: aflatoxin B1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental anatoxin (25 Lf per dose, adsorbed on Al phosphate)
Study: 31035187
Drug: Physostigmine salicylate
Normalized name: PHYSOSTIGMINE SALICYLATE
DrugBank: Physostigmine (DB00981)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine salicylate (0.04 mg/kg initial dose, followed by continuous infusion of 1 mg/h for 120 h)
Study: 28450262
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy using diode laser 660 nm mediated by methylene blue (MB)
Study: 28450262
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (kenakort A-orabase)
Study: 11777865
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 g intravenous single dose followed by oral cefixime
Study: 11777865
Drug: Daily intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intravenous dose of 1 g ceftriaxone
Study: 9693354
Drug: Combined hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined hormonal replacement therapy
Study: 9693354
Drug: Sequential hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential hormonal replacement therapy
Study: 2723991
Drug: Adult surgical
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adult surgical services (G-Surg)
Study: 23010962
Drug: αCa (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: αCa (calcium absorption)
Study: 16162254
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of 250 mg acetylsalicylic acid + 200 mg paracetamol + 50 mg caffeine (Thomapyrin)
Study: 16162254
Drug: All active
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All active treatments except caffeine
Study: 10439763
Drug: Ketamine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.15 mg/kg as a 5‐mL i.v. injection 5 min before surgery
Study: 10439763
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline 5 mL i.v. at the time of skin closure
Study: 10439763
Drug: Ketamine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.15 mg/kg i.v. at the time of skin closure
Study: 8574255
Drug: Mifepristone 600
Normalized name: Mifepristone 600 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 600 mg + Misoprostol 400 micrograms (1st dose) + Misoprostol 200 micrograms (2nd dose if needed)
Study: 8574255
Drug: Mifepristone 600
Normalized name: Mifepristone 600 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 600 mg + Misoprostol 400 micrograms (1st dose) + Misoprostol 600 micrograms (2nd dose)
Study: 8574255
Drug: Mifepristone 600
Normalized name: Mifepristone 600 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 600 mg + Misoprostol 400 micrograms (1st dose)
Study: 8574255
Drug: Mifepristone 600
Normalized name: Mifepristone 600 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 600 mg + Misoprostol 400 micrograms (1st dose) + Misoprostol 200 micrograms (2nd dose)
Study: 21385401
Drug: Telemonitoring intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telemonitoring intervention (daily self-measurements of respiratory-rate, heart-rate, blood pressure, oxygen saturation, weight, body temperature; daily qualitative symptom questionnaire; routine telephone contacts every fortnight)
Study: 17261216
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pretreatment of remifentanil (0.35 microg kg(‐1) min(‐1)) and premixture of lidocaine with propofol (1% propofol and 1% lidocaine in a 10:1 ratio)
Study: 17261216
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (remifentanil and lidocaine)
Study: 14871466
Drug: anti-TNF-alpha humanized
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-TNF-alpha humanized antibodies (infliximab)
Study: 3115846
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate transdermal patch (10 mg daily)
Study: 19539353
Drug: IA-BioHA (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA-BioHA (20 mg/2 ml)
Study: 11844646
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving anesthesia without epidural local anesthetics, postoperative analgesia with epidural morphine, and mobilization without fixed goals
Study: 10069276
Drug: Sufentanil concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil concentration of 1.5 ng/mL (group L)
Study: 10069276
Drug: Sufentanil concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil concentration of 3.0 ng/mL (group M)
Study: 10069276
Drug: Sufentanil concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil concentration of 4.5 ng/mL (group H)
Study: 10069276
Drug: Sufentanil concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil concentration of 1.7 ng/mL
Study: 7628181
Drug: 0.07 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.07 mg/kg midazolam
Study: 31858732
Drug: Small Changes
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small Changes (SC; make small daily changes in intake and activity)
Study: 25918933
Drug: Curcumin (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (45 mg/day) for 14 days before surgery
Study: 19237785
Drug: Single-stage adjustable
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-stage adjustable strabismus surgery (SSASS) under topical anesthesia and intravenous conscious sedation
Study: 14660132
Drug: Naloxone bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone bolus administered under anaesthetic
Study: 9032593
Drug: Fluconazole monotherapy
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole monotherapy
Study: 1355923
Drug: Idazoxan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idazoxan (20 mg, 40 mg, 80 mg)
Study: 30146783
Drug: Nitrogen plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrogen plasma treatment on one side of periorbital wrinkles with three sessions at a three-week interval
Study: 30146783
Drug: Nitrogen plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrogen plasma treatment
Study: 30146783
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (contralateral side without treatment)
Study: 27701661
Drug: OnabotulinumtoxinA (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: OnabotulinumtoxinA (200 U, cystoscopic intradetrusor injection)
Study: 25000668
Drug: Test dentifrice
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test dentifrice containing 1.5% arginine, an insoluble calcium compound and 1,450 ppm fluoride
Study: 11844821
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered eniluracil and 5-FU (1.0 mg/m2 with eniluracil in a 10:1 ratio, twice daily for 28 days)
Study: 10544991
Drug: Integrated drug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated drug and alcohol intervention (IDAI)
Study: 30975525
Drug: PCV10 (two-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV10 (two-dose schedule, group D)
Study: 27753182
Drug: transdermal oestradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: transdermal oestradiol (tE2)
Study: 27753182
Drug: luteinising hormone-releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: luteinising hormone-releasing hormone agonists (LHRHa)
Study: 24678746
Drug: Povidone iodine
Normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone iodine 2.5% solution irrigation
Study: 24678746
Drug: Preservative-free artificial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-free artificial tears and preservative-free antibiotic drops (without povidone iodine)
Study: 10713313
Drug: 3.8 g
Normalized name: dextrin 3 gram/3.8 gram ORAL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.8 g eicosapentaenoic acid/d
Study: 10713313
Drug: 3.6 g
Normalized name: ALCOHOL 3.6 g EXTRACORPOREAL CLOTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 g docosahexaenoic acid/d
Study: 10713313
Drug: 4.0 g
Normalized name: Menthol 4.0 g in 100 mL TOPICAL GEL [BIOCOOL ROLL TYPE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 g corn oil/d (placebo)
Study: 2867396
Drug: Oral immunisation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunisation with killed Haemophilus influenzae
Study: 29280191
Drug: Nutritional supplements
Normalized name: nutritional supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplements (at least 50% of the recommended dose)
Study: 24853829
Drug: Serial clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serial clopidogrel dose adjustment based on platelet function testing (PFT) during 12 months of dual antiplatelet therapy (DAPT). Patients took up to two additional 600 mg loading doses and a maintenance dose of 75-300 mg.
Study: 24853829
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard treatment without dose adjustment).
Study: 24853829
Drug: Interventional group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interventional group (with dose adjustment).
Study: 20562076
Drug: 50 IU/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 IU/kg heparin with an upper limit of 5,000 IU
Study: 20562076
Drug: 5,000 IU
Normalized name: bleopmycin 15,000 IU Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,000 IU heparin (standard dose)
Study: 17722960
Drug: Intranasal fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal fluticasone furoate 110 microg once daily for 2 weeks in adults and adolescents with seasonal allergic rhinitis
Study: 17722960
Drug: Intranasal fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal fluticasone furoate 110 microg once daily for 4-6 weeks in adults and adolescents with perennial allergic rhinitis
Study: 17722960
Drug: Intranasal fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal fluticasone furoate nasal spray in children aged 6-11 years for 2 weeks for seasonal allergic rhinitis
Study: 17722960
Drug: Intranasal fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal fluticasone furoate nasal spray in children aged 6-11 years for 4 weeks for perennial allergic rhinitis
Study: 17722960
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate nasal spray in adults, adolescents and children aged 2-11 years
Study: 15792815
Drug: 1500 mcg
Normalized name: cyanocobalamin 1500 MCG Chewable Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mcg mecobalamin daily for 2 years
Study: 11367647
Drug: Xuefuzhuyu Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuefuzhuyu Pill (XFZYP) 6 g, three times daily for one month
Study: 11367647
Drug: Aspirin 40
Normalized name: aspirin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 40 mg per day for one month
Study: 3142509
Drug: Alfentanil priming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil priming infusion (60 micrograms kg‐1 min‐1 for 10 min) followed by maintenance infusion (4.5 micrograms kg‐1 min‐1) with lorazepam 0.08 mg kg‐1 by mouth 1-2 h before operation.
Study: 3142509
Drug: Alfentanil maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil maintenance infusion rates of 5.4 (n = 4), 6.6 (n = 5), or 7.8 (n = 4) micrograms kg‐1 min‐1, each preceded by a proportional priming infusion with lorazepam 0.04 mg kg‐1 by mouth as premedication.
Study: 21176724
Drug: Erdosteine (E)
Normalized name: erdosteine
DrugBank: Erdosteine (DB05057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erdosteine (E) 300 mg b.i.d. for 10 days
Study: 18339162
Drug: Propofol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 0.5 mg/kg and ketamine 0.5 mg/kg
Study: 10926377
Drug: 4 puffs
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 puffs (0.4 mg) via MDI with spacer
Study: 10926377
Drug: 10 puffs
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 puffs (1.0 mg) via MDI with spacer
Study: 10926377
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg via SVN
Study: 14621850
Drug: OKT3 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKT3 (5 mg)
Study: 26673577
Drug: nab-paclitaxel 125
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel 125 mg/m2 plus carboplatin area under the curve 2 mg×min/mL